Clinical Trial Update: Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating intravitreal ranibizumab for choroidal neovascularization in ocular histoplasmosis syndrome; latest status is not provi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Histoplasmosis Syndrome

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Retina Associates of Kentucky | Conditions: Ocular Histoplasmosis Syndrome | Phase 1, Phase 2 | Status: UNKNOWN